- Home
- USEA vs IMNN Comparison
USEA vs IMNN Comparison
Compare USEA & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- IMNN
- Stock Information
- Founded
- USEA 2004
- IMNN 1982
- Country
- USEA Greece
- IMNN United States
- Employees
- USEA N/A
- IMNN N/A
- Industry
- USEA Marine Transportation
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- IMNN Health Care
- Exchange
- USEA Nasdaq
- IMNN Nasdaq
- Market Cap
- USEA 10.5M
- IMNN 12.1M
- IPO Year
- USEA N/A
- IMNN 1985
- Fundamental
- Price
- USEA $1.57
- IMNN $8.50
- Analyst Decision
- USEA
- IMNN Buy
- Analyst Count
- USEA 0
- IMNN 2
- Target Price
- USEA N/A
- IMNN $210.00
- AVG Volume (30 Days)
- USEA 23.4K
- IMNN 427.9K
- Earning Date
- USEA 08-12-2025
- IMNN 08-05-2025
- Dividend Yield
- USEA 2.56%
- IMNN N/A
- EPS Growth
- USEA N/A
- IMNN N/A
- EPS
- USEA N/A
- IMNN N/A
- Revenue
- USEA $42,595,000.00
- IMNN N/A
- Revenue This Year
- USEA N/A
- IMNN N/A
- Revenue Next Year
- USEA $11.62
- IMNN N/A
- P/E Ratio
- USEA N/A
- IMNN N/A
- Revenue Growth
- USEA N/A
- IMNN N/A
- 52 Week Low
- USEA $1.00
- IMNN $5.55
- 52 Week High
- USEA $2.78
- IMNN $47.40
- Technical
- Relative Strength Index (RSI)
- USEA 53.73
- IMNN 43.13
- Support Level
- USEA $1.56
- IMNN $6.51
- Resistance Level
- USEA $1.61
- IMNN $9.18
- Average True Range (ATR)
- USEA 0.08
- IMNN 1.27
- MACD
- USEA -0.01
- IMNN 0.34
- Stochastic Oscillator
- USEA 67.70
- IMNN 36.25
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).